Addressing a Global Crisis: Sapphire Pharma’s Mission to Improve Access to Life-Saving Medicines

Malaria, along with other infectious and autoimmune diseases, requires not only effective treatments but also affordable access to them. Sapphire Pharma aims to bridge this gap.

Malaria remains one of the most significant public health challenges worldwide. In 2023, an estimated 263 million malaria cases were reported globally, a sharp increase of 11 million cases from the previous year. The WHO African Region continues to bear the greatest burden, accounting for 94% of global cases. 

Despite significant progress over the past two decades, much work remains to combat the disease, which kills nearly 600,000 people each year. The global malaria burden highlights the urgent need for innovation in healthcare. Malaria, along with other infectious and autoimmune diseases, requires not only effective treatments but also affordable access to those treatments. Several malaria medicines show promise, but it remains difficult to access them globally. Sapphire Pharma is stepping in as a key player in bridging this gap.

Read more about our mission and strategic partnership: Addressing a Global Crisis: Sapphire Pharma’s Mission to Improve Access to Life-Saving Medicines | Worth